

Francesco Paneni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/709934/publications.pdf>

Version: 2024-02-01

119
papers

5,576
citations

94269

37
h-index

85405

71
g-index

121
all docs

121
docs citations

121
times ranked

8398
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. <i>Cardiovascular Research</i> , 2023, 118, 3374-3385.	1.8	10
2	Characterization of hemodynamic and metabolic abnormalities in the heart failure spectrum: the role of combined cardiopulmonary and exercise echocardiography stress test. <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	0.4	26
3	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2022, 118, 2385-2396.	1.8	14
4	Epigenetic remodeling in heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2022, 37, 219-226.	0.8	7
5	Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. <i>European Heart Journal</i> , 2022, 43, 1849-1860.	1.0	28
6	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 667-684.	2.5	15
7	Increased risk of incident diabetes in patients with long COVID. <i>European Heart Journal</i> , 2022, 43, 2094-2095.	1.0	4
8	Diabetes and heart failure: from disease mechanisms to personalized care. <i>Minerva Cardiology and Angiology</i> , 2022, 70, 341-343.	0.4	3
9	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. <i>European Heart Journal</i> , 2021, 42, 2590-2604.	1.0	74
10	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. <i>Cardiovascular Research</i> , 2021, 117, 2275-2288.	1.8	13
11	Deletion of fibroblast activation protein provides atheroprotection. <i>Cardiovascular Research</i> , 2021, 117, 1060-1069.	1.8	20
12	Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?. <i>Cardiovascular Research</i> , 2021, 117, 343-345.	1.8	3
13	Epigenetic Remodeling in Obesity-Related Vascular Disease. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1165-1199.	2.5	19
14	Cell-specific epigenetic changes in atherosclerosis. <i>Clinical Science</i> , 2021, 135, 1165-1187.	1.8	14
15	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021, 42, 1940-1958.	1.0	34
16	Disentangling the epigenetic landscape in cardiovascular patients: a path toward personalized medicine. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 331-345.	0.4	6
17	A "Once-and-Done"™ Approach to the Lifelong Reduction of Elevated Cholesterol. <i>European Heart Journal</i> , 2021, 42, 3820-3821.	1.0	1
18	Exploring RNA biomarkers in patients with acute myocarditis. <i>European Heart Journal</i> , 2021, 42, 3425-3426.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?. <i>European Heart Journal</i> , 2021, 42, 4211-4212.	1.0	1
20	Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 718741.	1.1	4
21	Molecular underpinnings of myocardial stiffness in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2021, 343, 80-82.	0.8	2
22	Inflammation in Metabolic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 742178.	1.1	42
23	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Diseaseâ€”From Bench to Bedside. <i>Frontiers in Physiology</i> , 2021, 12, 755060.	1.3	13
24	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving bloodâ€”brain barrier integrity: a translational study. <i>European Heart Journal</i> , 2020, 41, 1575-1587.	1.0	54
25	MicroRNA-122 in heart failure with reduced ejection fraction: Epiphenomenon or causal?. <i>International Journal of Cardiology</i> , 2020, 303, 66-67.	0.8	1
26	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. <i>Thrombosis and Haemostasis</i> , 2020, 120, 168-180.	1.8	13
27	New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 363-371.	1.0	12
28	Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 569358.	2.2	9
29	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	2.0	38
30	The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1 β . <i>Atherosclerosis</i> , 2020, 304, 30-38.	0.4	12
31	Epigenetic Control of Mitochondrial Function in the Vasculature. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 28.	1.1	39
32	Regression of left ventricular hypertrophy with SGLT2 inhibitors. <i>European Heart Journal</i> , 2020, 41, 3433-3436.	1.0	11
33	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis â€” Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 139, 24-32.	0.9	26
34	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. <i>European Heart Journal</i> , 2020, 41, 3884-3899.	1.0	58
35	The vascular epigenome in patients with obesity and type 2 diabetes: opportunities for personalized therapies. <i>Vascular Biology (Bristol, England)</i> , 2020, 2, H19-H28.	1.2	6
36	Sex-related differences in the ageing brain: time for precision medicine?. <i>Cardiovascular Research</i> , 2020, 116, 1246-1248.	1.8	2

#	ARTICLE	IF	CITATIONS
37	The Epigenome in Atherosclerosis. Handbook of Experimental Pharmacology, 2020, , 511-535.	0.9	5
38	PCSK9 in diabetes: sweet, bitter or sour?. European Heart Journal, 2019, 40, 369-371.	1.0	8
39	Thromboembolic Events Following Atrial Fibrillation Cardioversion and Ablation: What's the Culprit?. Medicina (Lithuania), 2019, 55, 505.	0.8	0
40	An overview of the molecular mechanisms underlying development and progression of bicuspid aortic valve disease. Journal of Molecular and Cellular Cardiology, 2019, 132, 146-153.	0.9	23
41	GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials. Vascular Pharmacology, 2019, 115, 64-68.	1.0	6
42	Interleukin-1 β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. Journal of Clinical Medicine, 2019, 8, 2072.	1.0	70
43	Epigenetic modulation of tenascin C in the heart. Journal of Hypertension, 2019, 37, 1861-1870.	0.3	19
44	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. European Heart Journal, 2019, 40, 997-1008.	1.0	69
45	Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology, 2019, 26, 709-727.	0.8	68
46	The epigenetic landscape in the cardiovascular complications of diabetes. Journal of Endocrinological Investigation, 2019, 42, 505-511.	1.8	21
47	Epigenetic processing in cardiometabolic disease. Atherosclerosis, 2019, 281, 150-158.	0.4	44
48	Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies. European Heart Journal, 2019, 40, e11-e13.	1.0	1
49	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. European Heart Journal, 2019, 40, 383-391.	1.0	45
50	Atrial fibrillation in the cardiometabolic patient. Minerva Medica, 2019, 110, 157-167.	0.3	12
51	Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury. International Journal of Cardiology, 2018, 260, 148-155.	0.8	64
52	Stem cell therapy in heart failure: Is the best yet to come?. International Journal of Cardiology, 2018, 260, 135-136.	0.8	2
53	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. European Heart Journal, 2018, 39, 4150-4158.	1.0	79
54	Epigenetics and cardiovascular regenerative medicine in the elderly. International Journal of Cardiology, 2018, 250, 207-214.	0.8	41

#	ARTICLE	IF	CITATIONS
55	Empagliflozin across the stages of diabetic heart disease. <i>European Heart Journal</i> , 2018, 39, 371-373.	1.0	9
56	Image integration guided ablation of left outflow tract ventricular tachycardia: Is coronary angiography still necessary?. <i>Indian Pacing and Electrophysiology Journal</i> , 2018, 18, 73-75.	0.3	1
57	Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke. <i>European Heart Journal</i> , 2018, 39, 3511-3517.	1.0	48
58	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. <i>International Journal of Cardiology</i> , 2018, 268, 179-186.	0.8	47
59	The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. <i>Kidney International</i> , 2018, 94, 49-59.	2.6	62
60	Authors' reply to Dr. Schmitz and Dr. Brand comments on "Epigenetics and Cardiovascular Regenerative Medicine in the Elderly". <i>International Journal of Cardiology</i> , 2018, 257, 274.	0.8	0
61	Predictors of Successful Ultrasound Guided Femoral Vein Cannulation in Electrophysiological Procedures. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2083.	0.5	6
62	The Aging Cardiovascular System. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1952-1967.	1.2	400
63	A call for safety during electrophysiological procedures: US in, why not US out?. <i>Europace</i> , 2017, 19, 2048-2048.	0.7	2
64	Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting. <i>American Heart Journal</i> , 2017, 188, 118-126.	1.2	11
65	Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways. <i>Cardiovascular Research</i> , 2017, 113, 498-507.	1.8	27
66	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. <i>Diabetes</i> , 2017, 66, 2472-2482.	0.3	139
67	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Medicine</i> , 2017, 130, S18-S29.	0.6	67
68	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017, 120, S17-S27.	0.7	66
69	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , 2016, 594, 2061-2073.	1.3	311
70	Residual SYNTAX score following coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 51, ezw356.	0.6	9
71	Stakeholders in non-Vitamin K antagonist oral anticoagulants prescription: the case of Italy. <i>Europace</i> , 2016, 18, 788.1-788.	0.7	2
72	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016, 203, 702-707.	0.8	39

#	ARTICLE	IF	CITATIONS
73	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016, 37, 1733-1737.	1.0	27
74	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016, 37, 572-576.	1.0	136
75	Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 150-158.	5.1	141
76	Molecular pathways of arterial aging. <i>Clinical Science</i> , 2015, 128, 69-79.	1.8	42
77	Shooting vascular oxidative stress: new hopes for stroke patients?: Figure 1. <i>European Heart Journal</i> , 2015, 36, 1573-1575.	1.0	5
78	Epidemiology, Definition, and Diagnosis of Diabetes Mellitus. , 2015, , 3-12.		2
79	Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. <i>European Heart Journal</i> , 2015, 36, 516-526.	1.0	37
80	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015, 36, 817-828.	1.0	75
81	Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 531-543.	0.9	30
82	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 403-6.	0.7	17
83	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , 2015, 6, 326.	1.3	51
84	Risk Stratification. , 2015, , 69-83.		0
85	Environment, Epigenetic Changes, and Cardiovascular Damage. , 2015, , 35-47.		0
86	Diabetes and cardiovascular disease: let's push forward with translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 407-11.	0.7	4
87	DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 471-8.	0.7	13
88	2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: Established knowledge and evidence gaps. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 5-10.	0.9	22
89	Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. <i>European Heart Journal</i> , 2014, 35, 2839-2848.	1.0	82
90	Abnormal Regulation of Renin Angiotensin Aldosterone System Is Associated With Right Ventricular Dysfunction in Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 188-194.	0.8	18

#	ARTICLE	IF	CITATIONS
91	Insulin Resistance, Diabetes, and Cardiovascular Risk. <i>Current Atherosclerosis Reports</i> , 2014, 16, 419.	2.0	129
92	Advanced glycation endproducts and plaque instability: a link beyond diabetes. <i>European Heart Journal</i> , 2014, 35, 1095-1097.	1.0	8
93	Intrinsic bleeding risk in patients with uninterrupted oral anticoagulation undergoing cardiac implantable electronic device procedures: A pilot study. <i>International Journal of Cardiology</i> , 2014, 176, 1420-1422.	0.8	1
94	p66Shc-induced redox changes drive endothelial insulin resistance. <i>Atherosclerosis</i> , 2014, 236, 426-429.	0.4	31
95	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 324-32.	0.7	30
96	Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. <i>Atherosclerosis</i> , 2013, 230, 191-197.	0.4	62
97	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013, 34, 2444-2452.	1.0	282
98	Mechanisms of Cardiovascular Aging. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013, 2, 275-283.	0.7	1
99	AngiomiR-126 expression and secretion from circulating CD34+ and CD14+ PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. <i>Blood</i> , 2013, 121, 226-236.	0.6	163
100	Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2482-2489.	0.8	33
101	Deletion of the Activated Protein-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction. <i>Circulation</i> , 2013, 127, 1229-1240.	1.6	90
102	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. <i>European Heart Journal</i> , 2013, 34, 2436-2443.	1.0	870
103	SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory. <i>Diabetes</i> , 2013, 62, 1800-1807.	0.3	96
104	Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , 2013, 34, 96-103.	1.0	72
105	Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. <i>Hypertension Research</i> , 2013, 36, 36-42.	1.5	28
106	Relation between right and left ventricular function in patients undergoing chronic dialysis. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 289-295.	0.6	20
107	Gene Silencing of the Mitochondrial Adaptor p66 ^{Shc} Suppresses Vascular Hyperglycemic Memory in Diabetes. <i>Circulation Research</i> , 2012, 111, 278-289.	2.0	219
108	p66 Shc as the Engine of Vascular Aging. <i>Current Vascular Pharmacology</i> , 2012, 10, 697-699.	0.8	21

#	ARTICLE	IF	CITATIONS
109	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2011, 149, 250-252.	0.8	11
110	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. <i>Current Hypertension Reports</i> , 2011, 13, 318-324.	1.5	31
111	Right Ventricular Dysfunction in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2010, 32, 432-438.	1.4	75
112	A case of thrombolysis in acute pulmonary embolism with right atrial thrombus: comparing current and past guidelines. <i>Internal and Emergency Medicine</i> , 2009, 4, 497-500.	1.0	1
113	Novel Lipids Targets in the Era of Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009, 16, 93-100.	1.0	1
114	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. <i>Clinical Science</i> , 2009, 116, 467-477.	1.8	122
115	The Growing Importance of Socioeconomic Aspects in Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 139-144.	1.0	0
116	Upcoming Challenges for Training in Cardiology. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 201-206.	1.0	1
117	The Microvolt T-Wave Alternans Test. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 213-219.	1.0	0
118	The Apelin/APJ System. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 159-162.	1.0	0
119	Epi-Drugs in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	17